Bridge to Life Ltd. has secured $110.0M in a Series C round, a significant infusion for a company quietly powering a critical corner of modern medicine: organ preservation. The funding arrives as the field pushes harder into machine perfusion and other technologies aimed at keeping organs viable longer and improving transplant outcomes.
The company, which supplies preservation solutions globally, was founded to bridge the gap between emerging science and the practical needs of organ procurement organizations and transplant centers. Its work leans heavily on collaboration with surgeons, and this capital gives it room to keep exploring that frontier-though specifics on how the money will be deployed were not disclosed.

















